These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35789365)

  • 1. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
    Janelidze S; Barthélemy NR; Salvadó G; Schindler SE; Palmqvist S; Mattsson-Carlgren N; Braunstein JB; Ovod V; Bollinger JG; He Y; Li Y; Raji CA; Morris JC; Holtzman DM; Ashton NJ; Blennow K; Stomrud E; Bateman RJ; Hansson O
    JAMA Neurol; 2024 Sep; 81(9):947-957. PubMed ID: 39068669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
    Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
    JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.
    Dyer AH; Dolphin H; O'Connor A; Morrison L; Sedgwick G; Young C; Killeen E; Gallagher C; McFeely A; Connolly E; Davey N; Claffey P; Doyle P; Lyons S; Gaffney C; Ennis R; McHale C; Joseph J; Knight G; Kelly E; O'Farrelly C; Fallon A; O'Dowd S; Bourke NM; Kennelly SP
    Alzheimers Res Ther; 2024 Aug; 16(1):186. PubMed ID: 39160628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
    Guo T; Li A; Sun P; He Z; Cai Y; Lan G; Liu L; Li J; Yang J; Zhu Y; Zhao R; Chen X; Shi D; Liu Z; Wang Q; Xu L; Zhou L; Ran P; Wang X; Sun K; Lu J; Han Y
    Mol Neurodegener; 2024 Jul; 19(1):58. PubMed ID: 39080744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
    Saloner R; VandeVrede L; Asken BM; Paolillo EW; Gontrum EQ; Wolf A; Lario-Lago A; Milà-Alomà M; Triana-Baltzer G; Kolb HC; Dubal DB; Rabinovici GD; Miller BL; Boxer AL; Casaletto KB; Kramer JH
    Alzheimers Dement; 2024 Jan; 20(1):376-387. PubMed ID: 37639492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
    McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
    J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
    VandeVrede L; La Joie R; Thijssen EH; Asken BM; Vento SA; Tsuei T; Baker SL; Cobigo Y; Fonseca C; Heuer HW; Kramer JH; Ljubenkov PA; Rabinovici GD; Rojas JC; Rosen HJ; Staffaroni AM; Boeve BF; Dickerson BC; Grossman M; Huey ED; Irwin DJ; Litvan I; Pantelyat AY; Tartaglia MC; Dage JL; Boxer AL
    JAMA Neurol; 2023 May; 80(5):495-505. PubMed ID: 37010841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.